Clinical Neuropharmacology最新文献

{"title":"The Principal Component of the Inflammatory Biomarkers is the Best Predictor of Neuropsychiatric Disorders in Long COVID Patients.","authors":"Hawraa Kadhem Al-Jassas, Hussein Kadhem Al-Hakeim","doi":"10.1097/WNF.0000000000000671","DOIUrl":"10.1097/WNF.0000000000000671","url":null,"abstract":"<p><strong>Objectives: </strong>Long COVID (LC) is associated with neuropsychiatric disorders (anxiety, depression, and fatigue), an insulin resistance (IR) state, and inflammatory biomarkers. In the present study, IR and inflammatory biomarkers were used to predict the scores of neuropsychiatric disorders.</p><p><strong>Methods: </strong>The ELISA method was used for measurements of IL-1β, IL-10, IL-18, C-reactive protein (CRP), and insulin in the sera of LC and control subjects. Glucose levels were measured spectrophotometrically. The Hamilton scale for anxiety (HAMA) and depression (HAMD), and the fibro fatigue scale (FFtotal) were used for scoring the neuropsychiatric symptoms. The homeostatic model assessment 2 (HOMA2) calculator was used for computing IR (HOMA2IR), insulin sensitivity (HOMA%S), and pancreatic β-cell function (HOMA%B).</p><p><strong>Results: </strong>LC is associated with neuropsychiatric diseases (FFtotal, HAMAtotal, and HAMDtotal), insulin resistance biomarkers, and inflammatory biomarkers. These biomarkers are correlated with each other in LC patients. The building of principal components for inflammatory biomarkers (PC_Inflam) and insulin resistance (PC_IR) creates vectors that could surpass individual biomarkers in neuropsychiatric issue prediction in liver cirrhosis patients. Out of the biomarkers investigated, PC_Inflam is the most important predictor for FFtotal (sensitivity and specificity of 71.4%), HAMAtotal (sensitivity and specificity of 70%), and HAMDtotal (sensitivity of 71.2% and specificity of 71.5%).</p><p><strong>Conclusions: </strong>Neuropsychiatric disorders can be predicted by the principal component built from inflammatory biomarkers (IL-1β, IL-10, IL-18, and CRP). In contrast, PC_IR has a lower predictive value for the neuropsychiatric disorders compared with PC_Inflam. These results indicated the significant role of inflammation in the main symptoms of LC.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"72-80"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amitriptyline for Refractory Idiopathic Intractable Hiccups: A Case Report.","authors":"Danial Chowdhury, Caitlin McCarthy, M Thomas Bateman","doi":"10.1097/WNF.0000000000000665","DOIUrl":"10.1097/WNF.0000000000000665","url":null,"abstract":"<p><strong>Objective: </strong>Intractable hiccups, which are hiccups that can last longer than 1 month, may be very debilitating for patients. With limited evidence and a lack of treatment guidelines, refractory hiccups can be difficult to manage. We aim to present a case of refractory idiopathic intractable hiccups treated with amitriptyline in conjunction with other medications shown to produce hiccups relief.</p><p><strong>Materials and methods: </strong>The patient's electronic health record, direct patient care experiences, and a systematic literature review were used for this case report. We report a 53-year-old male patient with refractory idiopathic intractable hiccups. Treatment was improved with the addition of amitriptyline to his regimen of medications used for hiccups management. Medline and PubMed were searched using the key terms \"hiccup\" or \"singultus\" and \"amitriptyline.\"</p><p><strong>Results: </strong>The literature search yielded 3 unique articles, which resulted in 4 unique cases with intractable hiccups responding to amitriptyline therapy. In all cases, patients tried multiple medications before amitriptyline initiation.</p><p><strong>Conclusions: </strong>This is the first case in over 30 years providing additional evidence for amitriptyline use in the relief of intractable hiccups. Amitriptyline may be more useful in patients experiencing intractable hiccups with comorbid mood disorders and in cases of suspected psychogenic origin.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"95-99"},"PeriodicalIF":1.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive Function and Treatment Outcomes in Trichotillomania: A Case Series Evaluating the Efficacy of TMS.","authors":"Beyazit Garip, Dilara Yüzgüleç","doi":"10.1097/WNF.0000000000000666","DOIUrl":"10.1097/WNF.0000000000000666","url":null,"abstract":"<p><strong>Objectives: </strong>Trichotillomania is a psychiatric disorder characterized by the compulsive pulling of one's own hair, eyelashes, or eyebrows. Depression and obsessive-compulsive disorder comorbidity is frequently observed in patients with trichotillomania. In this case series, we will report how a patient diagnosed with trichotillomania was successfully treated with transcranial magnetic stimulation (TMS) therapy in our clinic.</p><p><strong>Methods: </strong>The TMS protocol was delivered using the MagVenture X100 device, with treatment intensity calibrated to 100% of each participant's motor threshold. Following the established treatment protocol for trichotillomania, patients received repetitive TMS at 1 Hz, with each train lasting 300 seconds and a 60-second intertrain interval, for a total of 1200 pulses per session. The bilateral supplementary motor area (SMA) was targeted as the site of stimulation.</p><p><strong>Results: </strong>The efficacy of TMS in reducing hair-pulling behaviors in patients with trichotillomania was evaluated in a case series of 3 patients who underwent 20 TMS sessions. The findings demonstrated a significant reduction in hair-pulling behaviors post-treatment. According to the Massachusetts General Hospital Hair Pulling Scale (MGH-HP), over 50% improvement was observed in all patients.</p><p><strong>Conclusions: </strong>The findings suggest that TMS may serve as a promising intervention for trichotillomania, warranting further exploration in larger, controlled trials. The utilization of the MGH-HP scale provided a robust measure for assessing behavioral changes, highlighting the potential of TMS in managing compulsive disorders.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"91-94"},"PeriodicalIF":1.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Emergency Department and Psychiatric Boarding: A Model for the Future: 2026 Update.","authors":"David R Spiegel","doi":"10.1097/WNF.0000000000000663","DOIUrl":"10.1097/WNF.0000000000000663","url":null,"abstract":"","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"57"},"PeriodicalIF":1.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematological and Inflammatory Marker Changes Following Electroconvulsive Therapy in Bipolar Mania: A Quasi-Experimental Study.","authors":"Negar Heidari, Azad Maroufi, Narges Shams-Alizadeh","doi":"10.1097/WNF.0000000000000670","DOIUrl":"10.1097/WNF.0000000000000670","url":null,"abstract":"<p><strong>Objective: </strong>Neuroinflammation, reflected in hematological and inflammatory biomarkers, plays a role in bipolar disorder. Electroconvulsive therapy (ECT) is effective for treatment-resistant bipolar disorder, but its impact on these biomarkers remains unclear. This study investigated changes in hematological and inflammatory markers before and after ECT in bipolar mania and their association with treatment response.</p><p><strong>Methods: </strong>A quasi-experimental study was conducted on 30 inpatients with bipolar mania undergoing ECT. Blood samples were collected before anesthesia induction and 2 hours postseizure at the initial and final sessions. Hematological indices, including mean cell hemoglobin (MCH), red blood cell count (RBC), white blood cell count (WBC), mean corpuscular volume (MCV), and platelet count (Plt), along with inflammatory markers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), were analyzed. A ≥25% reduction in Young Mania Rating Scale (YMRS) scores defined clinical response.</p><p><strong>Results: </strong>CRP significantly increased after both the first ( P =0.01) and final ( P <0.001) ECT sessions. NLR ( P =0.001) and PLR ( P =0.002) showed a transient rise after the first session but not at the final session. Other hematological indices remained largely unchanged. No significant correlation was found between inflammatory marker changes and treatment response, though baseline CRP correlated with baseline YMRS scores ( P =0.013).</p><p><strong>Conclusions: </strong>ECT induces a transient inflammatory response, but these biomarker changes did not predict clinical improvement, suggesting systemic inflammation may not be central to ECT efficacy in bipolar mania. Further research is needed.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"58-65"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Deferiprone for Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","authors":"Deekshitha Alla, Dhruv Shah, Rakshna Ramsundar, Sai Lokesh Moraboina, Ritvik Rohan, Mrudula Alla, Sridevi Ravi, Soujanya Tirupati, Aradhya Singh, Chandana Priya Digumurthy, Jashika Mellamput","doi":"10.1097/WNF.0000000000000669","DOIUrl":"10.1097/WNF.0000000000000669","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD), the second most common neurodegenerative illness, is thought to have impacted 9.4 million people globally in 2020. The causation framework for Parkinson's disease is a combination of genetics, age, and environment. Iron chelators have been studied as potential treatment agents for Parkinson's disease (PD) because they can reduce oxidative stress and iron accumulation. Deferiprone (DFP) is one such drug.</p><p><strong>Objectives: </strong>To systematically review and analyze available clinical studies assessing the efficacy and safety of deferiprone in patients with Parkinson's disease, with particular focus on motor outcomes, iron accumulation, and adverse effects.</p><p><strong>Materials and methods: </strong>A comprehensive search was conducted in PubMed, Scopus, clinicaltrials.gov.in, and Web of Science databases, and a total of 3 studies were included and reviewed. The studies' baseline data included the first author's name, the year of the study, the place of the study, the number of subjects and controls, the mean age, gender, dosage, and route of DFP, the Estimated years of Disease (EYO), the MDS-UPDRS score, the PDQ-39 score, the MOCA score, the MMSE score, MRI T2 changes, and serum ferritin levels. Data regarding adverse effects and deaths were also extracted. A pooled analysis of the collected data was performed using R Studio.</p><p><strong>Results: </strong>The MDS-UPDRS score increased less in the test group's patients than in the placebo group (SMD=-0.69, 95% CI=-5.64 to 4.25, P =<0.00001, I 2 =98%). However, there was no significant difference between the 2 groups in the serum ferritin levels and the MRI T2 changes in caudate, nigra, pallidum, and putamen.</p><p><strong>Conclusion: </strong>Deferiprone shows potential in slowing motor symptom progression in Parkinson's disease, although its impact on brain iron levels remains inconclusive. Further large-scale, long-term studies are warranted to establish its clinical efficacy and safety.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"100-106"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Tolerability of Cenobamate in Treating Refractory Focal Epilepsy: Results From the 6-month Open-label Cenobamate in Focal Epilepsy Study (CIFES).","authors":"María Ruíz-Perelló, Francisco Salazar Hernández, Tatiana Espinosa Oltra, María López López, Juan Antonio García-Carmona","doi":"10.1097/WNF.0000000000000673","DOIUrl":"10.1097/WNF.0000000000000673","url":null,"abstract":"<p><strong>Objectives: </strong>Refractory epilepsy remains a major therapeutic challenge, affecting approximately one third of patients with persistent seizures despite treatment with multiple antiseizure medications (ASMs). Cenobamate (CNB), a novel ASM, has shown promising efficacy in both clinical trials and real-world settings. This observational study aimed to evaluate the efficacy, tolerability, and retention of CNB in adults with drug-resistant focal-onset seizures in routine clinical practice.</p><p><strong>Methods: </strong>A cross-sectional analysis was conducted on 40 patients treated with CNB at Santa Lucía University Hospital between 2022 and 2024. Seizure frequency, CNB discontinuation, adverse effects, and concomitant ASMs were assessed at 1, 3, and 6 months.</p><p><strong>Results: </strong>We found a significant reduction in mean monthly seizures, from 48.4 at baseline to 12.1 at 6 months ( P =0.0001). At 6 months, 48% of patients had a ≥50% seizure reduction, and 27% were seizure-free. In addition, CNB treatment was associated with a significant reduction in Defined Daily Doses and the number of concomitant ASMs. A 95% retention rate was observed among patients after 6 months on CNB treatment. Only 2 patients discontinued CNB, neither due to adverse effects. Reported adverse effects were mild to moderate, with somnolence (13%) and dizziness (10%) being the most common.</p><p><strong>Conclusions: </strong>These findings reinforce CNB as a valuable treatment option for patients with focal-onset drug-resistant epilepsy, supporting its integration into clinical practice. Further research is needed to evaluate long-term outcomes and its potential role as a first-line therapy.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"66-71"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroconvulsive Therapy for Refractory Anxiety and Depression in Superficial Siderosis: A Case Report.","authors":"Gregory Pierpoint, Krishan Saini","doi":"10.1097/WNF.0000000000000660","DOIUrl":"10.1097/WNF.0000000000000660","url":null,"abstract":"<p><strong>Objectives: </strong>To report the first documented case of anxiety and depression related to superficial siderosis that responded to electroconvulsive therapy (ECT).</p><p><strong>Methods: </strong>A 58-year-old man with traumatic superficial siderosis presented with panic attacks and major depressive disorder unresponsive to multiple pharmacologic trials. Brain MRI revealed hemosiderin deposition in cerebellar-limbic structures. A course of bifrontal brief-pulse ECT (8 sessions) was administered.</p><p><strong>Results: </strong>After 8 sessions, the patient experienced full remission of panic attacks and functional recovery. The PHQ-9 score decreased from 21 to 7, and the GAD-7 score decreased from 19 to 6, with sustained improvement at the six-week follow-up.</p><p><strong>Conclusions: </strong>This case suggests that ECT can safely and effectively target cerebellar-limbic circuit dysfunction in superficial siderosis and supports further investigation into neuromodulation for refractory psychiatric symptoms in this population.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"1-3"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145512058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RAP1A Variant rs7525578 Modifies Glycemic Response to Metformin But Not to Pioglitazone or Gliclazide in the UK Biobank.","authors":"Steven Lehrer, Peter Rheinstein","doi":"10.1097/WNF.0000000000000659","DOIUrl":"10.1097/WNF.0000000000000659","url":null,"abstract":"<p><strong>Objectives: </strong>Metformin is the first-line treatment for type 2 diabetes (T2D), yet interindividual variability in glycemic response remains poorly understood. Preclinical studies demonstrate that low-dose metformin lowers glucose via Rap1 signaling in ventromedial hypothalamic neurons, a pathway not required for sulfonylurea or thiazolidinedione efficacy. We investigated whether a common intronic RAP1A variant (rs7525578) modifies glycemic response to metformin in humans.</p><p><strong>Methods: </strong>We analyzed men with T2D and HbA1c >6% in the UK Biobank who were prescribed metformin (n=7002), pioglitazone (n=587), or gliclazide (n=2654). Genotypes were obtained from imputed array data. The mean HbA1c by genotype (CC, CT, and TT) was compared within each drug cohort using 1-way ANOVA with Tukey post hoc tests. Effect sizes were quantified using eta-squared (η2).</p><p><strong>Results: </strong>Among men prescribed metformin, rs7525578 was significantly associated with HbA1c (F=5.644, P=0.004, η2=0.0016). Heterozygotes (CT) had a higher mean HbA1c (7.52%) than CC homozygotes (7.39%, P=0.002). No significant associations were observed among pioglitazone (P=0.444) or gliclazide (P=0.233) users, and no effects were detected in women. The metformin-specific association remained after adjustment for combination therapy.</p><p><strong>Conclusions: </strong>The RAP1A variant rs7525578 is associated with modestly higher HbA1c among men treated with metformin, but not with pioglitazone or gliclazide. This drug-specific pharmacogenetic association mirrors mechanistic data in mice, supporting a role for Rap1 signaling in metformin action and highlighting pathway-based approaches to T2D pharmacogenetics.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"49 1","pages":"41-43"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Gantenerumab in Patients With Alzheimer Disease: A Systematic Review and Meta-analysis.","authors":"Deekshitha Alla, Aparna Malireddi, Rakshna Ramsundar, Dhruv Shah, Sai Santhosha Mrudula Alla, Arghadip Das, Adithya Andanappa, Nyassiri W Emmanuel, Sofia Siddiqui, Nitheesha R Marepalli, Rohit Rao Dugyala, Roohi Kolte","doi":"10.1097/WNF.0000000000000661","DOIUrl":"10.1097/WNF.0000000000000661","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer disease is the most common cause of dementia and a major global health concern with a significant impact on elderly individuals and society. Gantenerumab, a monoclonal antibody that targets aggregated amyloid beta and removes Aβ plaques, could potentially treat Alzheimer disease.</p><p><strong>Objectives: </strong>To systematically evaluate the safety of gantenerumab in patients with Alzheimer disease through a meta-analysis of available clinical studies.</p><p><strong>Materials and methods: </strong>A comprehensive literature search was conducted, and six studies were included. Extracted data included study year, location, sample size, age, gender, gantenerumab dosage, APOE4 status, cognitive scores, CSF biomarkers, PET-SUVr, Changes in mental function, hippocampal volume, PET-SUVr, adverse effects, and mortality. Analysis was done using the R software.</p><p><strong>Results: </strong>ADAS scores increased less in the gantenerumab group than in the placebo group (MD=-1.25, 95% CI:-1.40 to -1.10, P <0.00001, I ²=88%). The increase in the FAQ score was also smaller (MD=-0.82, 95% CI: -0.92 to -0.72, P <0.00001, I ²=87%). Hippocampal volumes significantly improved (right: MD=11.93, P =0.01; left: MD=12.24, P =0.008). However, gantenerumab was linked to higher rates of ARIA-E (OR=25.62, P <0.00001) and ARIA-H (OR=1.80, P <0.00001).</p><p><strong>Conclusion: </strong>In conclusion, patients with Alzheimer disease treated with gantenerumab showed significant improvement in the ADAS score, FAQ score, hippocampal volume, and CSF biomarkers compared with those treated with placebo. However, the use of gantenerumab is associated with a higher incidence of ARIA-E and ARIA-H.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"4-10"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}